Eczema severity was not significantly different when evaluated in all participants treated with ShA9. Still, a significant decrease in S. aureus and increased ShA9 DNA were seen and met secondary endpoints. Some S. aureus strains on participants were not directly killed by ShA9. Still, expression of mRNA for PSMα was inhibited in all strains. These observations demonstrate the safety and potential benefits of bacteriotherapy for atopic dermatitis. The gene discussed is FOLH1; the disease is atopic eczema.